On May 22, 2024, Tharimmune, Inc., a Delaware-incorporated clinical-stage biotechnology company, announced a 1-for-15 reverse stock split of its common stock, which is set to take effect after the market closes on May 24, 2024. The company's common stock will begin trading on a post-split basis on May 28, 2024, on The Nasdaq Capital Market under the same ticker symbol 'THAR'. This corporate action was approved by Tharimmune's stockholders during the Annual Meeting on May 14, 2024, and the final ratio was determined by the Board of Directors. The reverse stock split aims to bring Tharimmune into compliance with Nasdaq's minimum bid price requirement for continued listing. Following the reverse split, the company will have approximately 785,978 shares of common stock issued and...Show More

On May 22, 2024, Tharimmune, Inc., a Delaware-incorporated clinical-stage biotechnology company, announced a 1-for-15 reverse stock split of its common stock, which is set to take effect after the market closes on May 24, 2024. The company's common stock will begin trading on a post-split basis on May 28, 2024, on The Nasdaq Capital Market under the same ticker symbol 'THAR'. This corporate action was approved by Tharimmune's stockholders during the Annual Meeting on May 14, 2024, and the final ratio was determined by the Board of Directors. The reverse stock split aims to bring Tharimmune into compliance with Nasdaq's minimum bid price requirement for continued listing. Following the reverse split, the company will have approximately 785,978 shares of common stock issued and outstanding. Adjustments will also be made to outstanding equity-based awards and other equity rights. Tharimmune specializes in developing therapies for rare, inflammatory, and oncologic diseases and holds an exclusive worldwide license for a clinical-stage asset to treat pruritis in PBC, a rare liver disease. The company's immuno-oncology pipeline includes novel antibodies targeting PD-1, HER2, and HER3.